Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 - Clinical Trial Optional)
ID: 336481Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $275K

Eligible Applicants

Others

Funding Category

Income Security and Social Services

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/336481

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-21-355.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns" (R21), aimed at developing novel screening tests and therapeutic interventions for conditions identified through newborn screening. This initiative encourages research on both established and "high priority" genetic disorders that could benefit from early identification and treatment, emphasizing the critical role of early diagnosis in improving health outcomes for infants. The grant supports exploratory projects with a budget ceiling of $275,000, to be completed within two years, and is open to a wide range of eligible applicants, including academic institutions and community-based organizations. Interested parties should submit their applications by November 16, 2024, and can find more information at the provided NIH link or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.

    Point(s) of Contact
    OERWebmaster03@od.nih.gov
    Files
    Title
    Posted
    PAR-21-355-Full-Announcement.html
    PAR-21-355.html
    The Department of Health and Human Services has announced a funding opportunity titled "Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns" (R21). This initiative, led by the National Institutes of Health (NIH) through the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), focuses on developing novel screening tests and therapeutic interventions for conditions identified through newborn screening. Emphasizing the importance of early diagnosis and intervention, the grant encourages research on both established and "high priority" disorders that could benefit from early identification. The funding supports projects that are exploratory and can be completed within two years, with a budget not exceeding $275,000 total. Applications must comply with NIH application instructions, and various organizations, including academic institutions and nonprofits, are eligible to apply. The NIH aims to expand the scope of newborn screening programs to utilize advanced technologies and improve health outcomes for infants. The announcement outlines timelines, eligibility requirements, and evaluation criteria for applications, ensuring alignment with the overarching goal of enhancing newborn health through effective screening and treatment strategies.
    Similar Opportunities
    Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R01 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns," aimed at advancing research in novel screening methods and therapeutic interventions for genetic conditions identified through newborn screening. This initiative encourages the development of innovative screening assays, the use of artificial intelligence, and the exploration of socio-economic implications related to newborn screening, with a focus on conditions that may benefit from early detection and treatment. The grant supports long-term research projects (R01) and is open to a diverse range of applicants, including higher education institutions and community-based organizations, with applications accepted until November 16, 2027. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-265.html.
    Natural History of Disorders Screenable in the Newborn Period (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Natural History of Disorders Screenable in the Newborn Period (R01 Clinical Trial Optional)" aimed at expanding knowledge of disorders that are currently or may become part of statewide newborn screening programs. This initiative seeks to gather comprehensive data on the natural history of these conditions to facilitate appropriate interventions for affected infants, improve diagnostic accuracy, and support the development of targeted treatments. The funding will assist in identifying biological mechanisms, understanding genetic diversity, and establishing data collection systems for longitudinal studies, emphasizing the importance of research in newborn screening. Interested applicants, including various educational and community organizations, can submit proposals with a maximum project period of five years, with the funding cycle opening on January 5, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-25-227.html.
    Natural History of Disorders Screenable in the Newborn Period (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for research into the natural history of disorders detectable through newborn screening, under the grant title "Natural History of Disorders Screenable in the Newborn Period (R01 Clinical Trial Optional)." This initiative aims to enhance understanding of these disorders to support early identification and intervention, focusing on improving diagnostic accuracy, elucidating genetic and clinical heterogeneity, and exploring underlying mechanisms to inform treatment options. The funding is available for new, renewal, resubmission, or revision applications, with a maximum support period of five years and no cost-sharing requirement. Interested applicants, including various educational and community organizations, must submit proposals by January 7, 2025, and can reach out to the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV for assistance or further information.
    Screening and Functional Validation of Human Birth Defects Genomic Variants (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Screening and Functional Validation of Human Birth Defects Genomic Variants (R01 Clinical Trial Not Allowed)" aimed at advancing research on congenital defects linked to genetic variants. This initiative encourages the use of cutting-edge genotyping and sequencing technologies to validate genetic variants identified through public databases, bridging the gap between variant identification and understanding their functional impacts on developmental outcomes. The funding is available to a diverse range of eligible organizations, including higher education institutions and nonprofits, with an annual budget cap of $499,999 and a project period of up to five years. Interested applicants should contact the NIH OER Webmaster at grantsinfo@nih.gov for assistance and must submit their proposals by May 7, 2025, to be considered for this significant funding opportunity.
    Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)" aimed at advancing precision medicine for pregnant individuals, lactating persons, and children. This grant seeks to support innovative research that develops novel tools and technologies, enhances understanding of drug mechanisms, and improves therapeutic options for these populations, particularly those with disabilities. The initiative is part of the R21 Exploratory/Developmental Research Grants program, with a funding cap of $275,000 over a potential two-year period, and requires a Data Management and Sharing Plan as part of the application process. Interested applicants can find more information and submit inquiries via email at grantsinfo@nih.gov, with the application deadline set for May 7, 2026.
    Advancing Research to Understand Congenital Malformations (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Advancing Research to Understand Congenital Malformations (R01 Clinical Trial Not Allowed)" aimed at supporting innovative research into the mechanisms underlying structural birth defects. This initiative encourages applicants to utilize advancements in genetics, omics methods, and synthetic biology to explore genetic, environmental, and epigenetic factors contributing to these anomalies, which affect approximately 3% of live births in the U.S. The grant allows for budgets up to $499,999 in direct costs per year, with project periods not exceeding five years, and applications are due by February 5, 2025. Interested parties can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed) to support innovative early-stage research projects that may lead to significant advancements in biomedical, behavioral, or clinical fields. This grant is designed to encourage high-risk, high-reward research, providing funding for projects that are distinct from traditional R01 grants, with a maximum budget of $275,000 over a two-year period, and no more than $200,000 in any single year. Eligible applicants include a wide range of organizations such as educational institutions, nonprofit organizations, and tribal governments, with applications undergoing a rigorous peer review process to assess their innovation and feasibility. Interested parties should note that the application submission period begins on January 16, 2025, with the opportunity closing on January 7, 2028; for further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Required) to support innovative research projects in the early stages that can lead to significant advancements in biomedical, behavioral, and clinical research. This funding opportunity requires applicants to propose at least one clinical trial and is aimed at addressing critical gaps in knowledge within the scientific missions of participating NIH Institutes and Centers. Eligible applicants include a diverse range of organizations, such as higher education institutions, nonprofits, and foreign entities, with a total project period limited to two years and a budget of up to $275,000. The application period opens on January 16, 2025, and closes on January 8, 2028; interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)" aimed at advancing research in drug safety and effectiveness for pregnant individuals, lactating persons, and children. This initiative seeks to support innovative projects that develop novel methodologies, enhance understanding of drug mechanisms, and promote precision medicine to address significant unmet medical needs in maternal and pediatric health. Eligible applicants include a wide range of institutions, such as historically black colleges and universities, tribal colleges, and various nonprofit organizations, with funding available up to $275,000 over a two-year period. Interested parties should note that applications are accepted until December 16, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Screening and Functional Validation of Genomic Variants Associated with Human Congenital Anomalies (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the screening and functional validation of genomic variants associated with human congenital anomalies through the R01 Clinical Trial Not Allowed grant. This initiative aims to leverage advancements in genomic technologies to identify and validate genetic variants linked to congenital defects, intellectual developmental disabilities, and inborn errors of metabolism, thereby bridging the gap between genetic identification and functional impact on health. Eligible applicants include a wide range of institutions such as universities, nonprofits, and tribal governments, with a maximum budget of $499,999 per project year and a project duration of up to five years. Interested parties should submit their applications by January 7, 2028, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-185.html for further details.